Thanks to AI, data science tasks that once demanded specialized skills can now be performed faster, more accurately and at a ...
Q3 2025 Management View Ian Mortimer, President and CEO, highlighted three critical priorities: completion of the Phase III X ...
Fabhalta and Vanrafia Phase III analyses, Fabhalta real-world treatment pattern data, and zigakibart Phase I/II trial showcase strength of IgA nephropathy (IgAN) portfolioC3 glomerulopathy (C3G) studi ...
Findings further demonstrate the effectiveness of Roche’s approved medicines in advancing treatment standards for people with ...
OpenAI, Oracle, and Related Digital plan a $7B data center campus in Michigan, promising thousands of jobs, DTE-backed power, and a LEED closed-loop design.
Servier today announced longer-term data from the Phase 3 INDIGO trial evaluating VORANIGO® (vorasidenib) versus placebo in patients with Grade 2 mutant isocitrate dehydrogenase 1 or 2 (mIDH1/2) ...